Dapagliflozin & Teneligliptin Tablets – Dual Pathway Control in Type 2 Diabetes.
TENLITUS DP 20/10: The dual composition of Teneligliptin 20 mg + Dapagliflozin 10 mg offers a synergistic approach to managing Type 2 Diabetes Mellitus. Teneligliptin increases incretin hormones to stimulate insulin release and suppress glucagon. Dapagliflozin increases urinary glucose excretion by inhibiting the SGLT2 transporter in renal proximal tubules. Together, they improve HbA1c levels, reduce fasting and postprandial glucose, and support weight management without increasing insulin levels or appetite.
Recommended by Specialists:
✅General Physicians: It is preferred to treat the disease associated with routine diabetes care and follow-up treatment.
✅Endocrinologists: It is preferred to treat the disease associated with specialised diabetes management.
Key benefits of Dapagliflozin & Teneligliptin Tablets – TENLITUS DP 20/10:
✅Complementary Mechanisms for Glycemic Control – Teneligliptin enhances insulin secretion via DPP-4 inhibition, while Dapagliflozin promotes glucose excretion through the kidneys via SGLT2 inhibition.
✅Reduced Risk of Hypoglycemia – The glucose-dependent action of both agents minimises hypoglycemic episodes, making it safer for long-term use.
✅Added Cardiorenal Benefits – Dapagliflozin supports heart and kidney function, which benefits diabetic patients with comorbidities.
INDICATIONS:
✅Type 2 Diabetes Mellitus
✅Inadequate Glycemic Control on Monotherapy
✅Patients at Risk of Cardiovascular or Renal Complications
✅Overweight or Obese Diabetic Patients










